| ID | Sequence | Length | GC content |
|---|---|---|---|
| GAAGCACCGGUGAGUGGGCAGGGGCUCCCUCCCCAUCAAUAGGGCCGAC… | 1630 nt | 0.5957 | |
| GCCCGCCUCCUGCGCCGCCCCUUCCGAGGCUAAAUCGGCUGCGUUCCUC… | 1640 nt | 0.6055 | |
| GCCCGCCUCCUGCGCCGCCCCUUCCGAGGCUAAAUCGGCUGCGUUCCUC… | 1486 nt | 0.6077 | |
| CUUAAAAAAAACCAGGGCUCCAGAGAAUCAGAACAGCCACCAUCACCGC… | 1569 nt | 0.5819 |
This gene encodes a member of the class I fructose-bisphosphate aldolase protein family. The encoded protein is a glycolytic enzyme that catalyzes the reversible conversion of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone phosphate. Three aldolase isozymes (A, B, and C), encoded by three different genes, are differentially expressed during development. Mutations in this gene have been associated with Glycogen Storage Disease XII, an autosomal recessive disorder associated with hemolytic anemia. Disruption of this gene also plays a role in the progression of multiple types of cancers. Related pseudogenes have been identified on chromosomes 3 and 10. [provided by RefSeq, Sep 2017]
A study in humans demonstrated that the ALDOA is part of a six-protein panel, including THBS1, C3, RSU1, GSTO1, and TLN1, which demonstrated high diagnostic accuracy for sudden cardiac death risk in patients with hypertrophic cardiomyopathy when analyzed using ultraperformance liquid chromatography-tandem mass spectrometry [Cătinas et al. DOI:10.3390/ijms26146818]. A review of human studies summarized that the ALDOA is part of a six-protein panel (including THBS1, C3, RSU1, GSTO1, and TLN1) with high diagnostic accuracy for predicting sudden cardiac death risk in patients with hypertrophic cardiomyopathy, as identified using ultraperformance liquid chromatography-tandem mass spectrometry [Raluca-Maria Cătinas; Sorin Hostiuc DOI:10.3390/ijms26146818].